High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer.
Thirteen patients with transitional cell carcinoma of the bladder received monthly circadian-timed doxorubicin and cisplatin chemotherapy immediately after radical cystectomy. In five patients cancer had spread through the serosa of the bladder wall and/or into the perivesical fat (stage C). In eight patients cancer had spread to other pelvic tissues and pelvic lymph nodes (stage D1). Ten of these 13 patients showed no recurrence of disease after a median follow-up period of 3.5 years (range, 1 to greater than 5.5); these patients received no chemotherapy for a median duration of 3 years (range, 2-5). Two of the three patients who ultimately failed had local tumor recurrence which occurred much later than is the usual case (40 and 52 months). This circadian-timed two-drug regimen, given in full doses for nine courses as adjuvant treatment, delays and may prevent local and distant recurrence of stage C and D1 bladder cancer.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D004317:Doxorubicin; D002945:Cisplatin